Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Co.'s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. We show 37 historical shares outstanding datapoints in our coverage of QURE's shares outstanding history.
Understanding the changing numbers of QURE shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like QURE versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching QURE by allowing them to research QURE shares outstanding history
as well as any other stock in our coverage universe. |
Free QURE Email Alerts:
Video: Shares Outstanding Importance
